Mesoblast Limited (MEOBF)
| Previous Close | 0.6242 |
| Open | 0.6416 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6416 - 0.6416 |
| 52 Week Range | 0.4400 - 1.4700 |
| Volume | |
| Avg. Volume | 1,429 |
| Market Cap | 415.378M |
| Beta (5Y Monthly) | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1560 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 33%, or US$6.8 million, to US$13.9 million compared with US$20.7 million in the comparative q
- GlobeNewswire
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled “Late-Stage Advancements in Heart Failure Therapeutics and Management”, presented by Maxim Group LLC and hosted by
- Simply Wall St.
The past five years for Mesoblast (ASX:MSB) investors has not been profitable
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
